GARDEN (Global Hematological Rare Diseases Alliance)/LinkedIn
May 23, 2026, 14:42
How Should Evidence Be Interpreted in Modern Hemophilia Care? – GARDEN
GARDEN (Global Hematological Rare Diseases Alliance) shared a post on LinkedIn:
“How should evidence be interpreted in modern hemophilia care?
In this new contribution from the GARDEN editorial series, Prof. Cedric Hermans explores the methodological debate behind international hemophilia guidelines, examining the balance between randomized clinical trials, real-world evidence, and patient-centered decision-making.
A critical reflection on how evidence shapes clinical practice, access to care, and the future of hemophilia management.”
Stay updated with Hemostasis Today.
-
May 23, 2026, 12:52Fernanda Orsi: Honor to Be Speaking on ITP Diiferential Diagnosis at the 2026 Highlights of ASH
-
May 23, 2026, 12:46Jayagowri Karthikeyan: Grateful to Receive NBEMS President’s Gold Medal for Excellence In Immunohematology and Blood Transfusion
-
May 23, 2026, 12:40Aryabhatta Sadhu: Redefining Transfusion Medicine Across Obstetrics, Gynecology, and Fetal Medicine
-
May 23, 2026, 12:03Kiana Mohammadian: Do Anti-Inflammatory Cytokines Modulate Thrombosis?
-
May 23, 2026, 11:55Zikra Tazeen Mohammad Zakriya: Exploring the Link Between Vitamin D, Stroke, and Thrombosis
-
May 23, 2026, 11:33Alessandra Bosch: Swiss Delphi Consensus Study on Thrombophilia Testing Indications
-
May 23, 2026, 11:21Dip Ghosh: How CPDA-1 Keeps Transfusions Safe and Effective
-
May 23, 2026, 08:15Alexander Krupp: Asundexian Receives Priority Review Designation from China‘s NMPA
-
May 23, 2026, 07:59Toward a Dedicated Framework for MIg-Driven Hemostatic Disorders – JTH